EcoR1 Capital: Platform Profile

Overview

EcoR1 Capital is a San Francisco biotech-focused investment manager founded by Oleg Nodelman in 2013. It invests in companies across stages of research and development and emphasizes scientific diligence, management quality and financing strategy.

Its platform includes public-biotech holdings and venture/private-company investing.

May fit better for

• investors seeking specialist biotechnology exposure;
• allocators comfortable with scientific and clinical diligence;
• investors seeking public/private biotech crossover exposure;
• qualified investors able to tolerate binary clinical and regulatory outcomes.

May fit less well for

• investors seeking broad sector diversification;
• retail users seeking public self-service access;
• users who treat the 13F as the complete venture/public portfolio;
• investors uncomfortable with clinical-stage volatility and financing risk.

Current regulatory AUM is $3.425B

• Regulatory AUM: $3.425B
• Regulatory AUM exact: $3,424,668,843
• Regulatory AUM as of: 2026-03-30
• Account count: 5
• Employees: 22

Current private-fund GAV equals the reported RAUM amount

• Private fund count: 5
• Private fund gross assets: $3.425B

Q2 2026 13F value is $2.057B

Official SEC summary:

• Q2 2026 13F value: $2.057B
• Q2 2026 13F exact value: $2,056,733,459
• Q2 2026 13F as of: 2026-06-30
• Q2 2026 13F entry count: 33

• Form 13F market value equals regulatory AUM: No
• Form 13F equals complete portfolio: No

Private-company investments are not fully represented by the filing.

First-party identity is biotech and therapeutic innovation

• Biotech focused: Yes
• Therapeutic innovation: Yes
• Public company investing: Yes
• Venture private investing: Yes
• Scientific diligence: Yes
• Management quality focus: Yes
• Financing strategy focus: Yes

Founder disclosures show:

• Founder portfolio manager: Oleg Nodelman
• Firm established: 2013

Venture portfolio display is not current fund NAV

EcoR1 says its displayed venture portfolio is representative of the full venture portfolio since inception and includes exits/acquisitions.

Historical and exited investments should not be counted as current holdings.

Form D confirms private-fund structures

Current 2026 amendments exist for EcoR1 private funds, including 3(c)(1) and 3(c)(7) vehicles.

• Private fund offerings exist: Yes
• Form d equals public retail access: No
• Public self service retail signup: No

Assessment

EcoR1's Q2 13F captures a concentrated public-biotech portfolio, but the manager's own site makes clear that venture/private investing is also core. The $2.057B filing therefore cannot replace $3.425B of RAUM.